AstraZeneca (AZN) Tops Q1 EPS by 12c
Get Alerts AZN Hot Sheet
Join SI Premium – FREE
AstraZeneca (NYSE: AZN) reported Q1 EPS of $1.05, $0.12 better than the analyst estimate of $0.93. Revenue for the quarter came in at $6.35 billion versus the consensus estimate of $5.95 billion.
Financial guidance for FY 2020 is unchanged. Total Revenue is expected to increase by a high single-digit to a low double-digit percentage and Core EPS is expected to increase by a mid- to high-teens percentage. AstraZeneca recognises the heightened risks and uncertainties from the impact of COVID-19 referred to above.
For earnings history and earnings-related data on AstraZeneca (AZN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Chicopee Bancorp (CBNK) Tops Q1 EPS by 1c
- NBT Bancorp (NBTB) Reports in-line Q1 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!